Dendreon names new CEO; Agilvax lands $2M in Series A; Merck's Zostavax effective after chemo;

> Dendreon ($DNDN) has appointed retired biotech exec W. Thomas Amick as its new CEO. Story

> New Mexico-based Agilvax has scored $2 million in Series A funding to develop its virus-like particle technology. Report

> Merck's ($MRK) shingles vaccine Zostavax remains effective after chemotherapy, a study found. Release

> PaxVax has named Jonathan Klock as its North American sales and marketing VP and Jeremy Gowler as its VP of global marketing. Release

> GeoVax has entered a clinical development license agreement with Valneva for its HIV/AIDS vaccines. Release

> The NIH has awarded $3.5 million in grants to Profectus BioSciences for HIV-related vaccine development. More

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.